Q3 FY2026 · ended Sep 30, 2026 · Revenue $0 · Filed Nov 4, 2026
Rapport Therapeutics, Inc. (RAPP) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $0 and a net loss of $40.2 million. Free cash flow was -$41.6 million. As of Sep 30, 2026 it held $395.0 million in cash and investments and $9.4 million in total debt.
Revenue
$0
Net income
$-40.23M
-49.4% vs year-ago quarter
Operating cash flow
$-41.63M
-138.4% vs year-ago quarter
Free cash flow
$-41.63M
-136.6% vs year-ago quarter
EPS
$-0.84
-18.3% vs year-ago quarter
Dividend per share
None
Shares outstanding
59.28M
+24.4% vs year-ago quarter
Net cash
$385.64M
Q3 FY2026
Operating margin
-121.1%
Q1 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- RAPP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2012593
- Former names
- Rapport Therapeutics, Inc. (until Nov 4, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $20.0M | — | — |
| Operating income | -$44.1M | -$60.8M | -$24.2M | -$38.5M | -$30.0M |
| Net income | -$40.2M | -$56.6M | -$19.9M | -$33.8M | -$26.9M |
| Diluted EPS | -$0.84 | -$1.19 | -$0.42 | -$0.72 | -$0.71 |
| Operating cash flow | -$41.6M | -$41.5M | -$13.1M | -$24.7M | -$17.5M |
| Free cash flow | -$41.6M | -$41.5M | -$13.1M | -$24.9M | -$17.6M |
| Total assets | $418.6M | $459.0M | $497.6M | $512.4M | $535.3M |
| Total liabilities | $27.4M | $36.1M | $26.1M | $27.8M | $23.7M |
| Stockholders' equity | $391.2M | $422.9M | $471.5M | $484.7M | $511.6M |
| Cash and investments | $395.0M | $436.1M | $476.8M | $490.5M | $513.0M |
| Total debt | $9.4M | $10.1M | $10.8M | $11.5M | $11.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, New debt, Unregistered share sale
|
Oct 30, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 20, 2026 | Oct 20, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
All 253 Rapport Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.